Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Boehringer Ingelheim
Harvard Business School

Last Updated: November 29, 2021

DrugPatentWatch Database Preview

Patent: 10,420,761

➤ Subscribe for complete access

« Back to Dashboard

Summary for Patent: 10,420,761
Title:Allosteric inhibitors of thymidylate synthase
Abstract: The current invention is directed to a class of compounds that inhibit the function of Thymidylate synthase. Thymidylate synthase inhibition was noted to result in inhibition of tumor cell grow and killing of tumor cells. Thymidylate synthase inhibition is, thus, useful for treatment of various types of cancers, including but not limited to, acute lymphoblatic leukemia (ALL), acute myelogenous leukemia (AML), acute promyelocytic leukemia, chronic lymphocytic leukemia (CLL), chronic myelogenous leukemia (CML), acute monocytic leukemia (AMOL), hairy cell leukemia, large cell immunoblastic lymphoma, plasmacytoma, multiple myeloma, Hodgkin\'s lymphoma, non-Hodgkin\'s lymphoma, leukemia, brain cancer, lung cancer, central nervous system (CNS) cancer, melanoma, renal cancer, prostate cancer, colon cancer, ovarian cancer and breast cancer. The compounds disclosed herein can be used alone or in combination with other cancer treatment regimens (e.g., radiation therapy and/or other chemotherapeutic agents that are administered to a subject having a tumor, cancer or neoplasia).
Inventor(s): Zajac-Kaye; Maria (Gainesville, FL), Kulemina; Lidia (Destin, FL)
Assignee: University of Florida Research Foundation, Inc. (Gainesville, FL)
Application Number:14/773,906
Patent Claims:see list of patent claims

Details for Patent 10,420,761

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Clinigen, Inc. PROLEUKIN aldesleukin For Injection 103293 1992-05-05 ⤷  Try it Free 2033-03-15
Amgen, Inc. NEUPOGEN filgrastim Injection 103353 1991-02-20 ⤷  Try it Free 2033-03-15
Amgen, Inc. NEUPOGEN filgrastim Injection 103353 2000-06-28 ⤷  Try it Free 2033-03-15
Genentech, Inc. RITUXAN rituximab Injection 103705 1997-11-26 ⤷  Try it Free 2033-03-15
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.